Phenazone metabolism in patients with liver disease.
Phenazone metabolism was studied in 14 patients with liver disease and six normal volunteers. The plasma and renal clearance of phenazone and the 4-hydrozyphenazone excretion in urine was significantly decreased in the patients with liver disease. The urinary excretion of 4-hydroxyphenazone was significantly correlated to the plasma clearance of phenazone (r= + 0.95, P less than 0.001), to quantitative liver function as measured by the galactose elimination capacity (r= + 0.95, P less than 0.001), and to the prothrombin values (r= + 0.82, P less than 0.001). The determination of the 4-hydroxyphenazone excretion in urine may be used as an easy and non-invasive test of quantitative liver function.
D000328:Adult; D000368:Aged; D000983:Antipyrine / Q000378:metabolism*; D003404:Creatinine / Q000378:metabolism; D005690:Galactose / Q000378:metabolism; D006801:Humans; D007275:Injections, Intravenous; D007700:Kinetics; D008107:Liver Diseases / Q000175:diagnosis / Q000378:metabolism*; D008111:Liver Function Tests / Q000379:methods; D008297:Male; D008875:Middle Aged
D003404:Creatinine; D000983:Antipyrine; D005690:Galactose